Article

Hydrophobic acrylic IOL combines predictable correction, rotational stability

The enVista Toric IOL was launched by Bausch + Lomb at the 2012 Congress of European Society of Cataract and Refractive Surgeons.

Milan, Italy-The enVista Toric IOL was launched by Bausch + Lomb at the 2012 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) here.

As Bausch + Lomb’s first hydrophobic acrylic IOL for astigmatism correction, the lens features a unique single-piece, modified-C haptic design that delivers superior rotational stability compared with other IOLs, the company said in a prepared statement. The haptics feature a step-vaulted design to secure a predictable astigmatism correction and minimize posterior capsular opacification. The combination of aspheric, aberration-free technology with a glistening-free hydrophobic acrylic material helps the lens deliver a new standard in patient outcomes, according to the company.

“The new enVista Toric lens . . . extends the unique benefits of the enVista lens launched at ESCRS last year. The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary,” said Cal Roberts, MD, executive vice president and chief medical officer, Bausch + Lomb. “The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”

The enVista Toric lens has two key features that enhance its rotational stability: unique fenestrated, step-vaulted haptics and a 56° contact angle to provide added stability. The lens is easily implantable through a 2.2-mm incision.

The enVista TORIC lens received CE Mark approval in the European Union in April 2012 and is not approved for sale in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.